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Oxygenated derivatives of cholesterol are believed to play a role in cellular cholesterol homeostasis through 
the feed-back control of its biosynthesis. We report hat 26-hydroxycholesterol inhibits the specific binding, 
uptake and degradation of t25I-LDL in human fibroblasts. The effect is dose-dependent, and saturation ki- 
netics indicates a reduction of LDL-binding sites with no effect on iigand affinity. The results support a 
possible role of 26-hydroxycholesterol, a physiological oxysterol, in the regulation of cellular cholesterol 
homeostasis. 
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1. INTRODUCTION 
Human fibroblasts in culture derive their 
cholesterol from endogenous biosynthesis and 
from receptor-mediated uptake of low density 
lipoproteins (LDL) [1]. Oxygenated sterols repress 
3-hydroxy-3-methylglutaryl coenzyme A (HMG- 
CoA) reductase (EC 1.1.1.34) activity [1-3], and 
one of them is reported to decrease the specific 
binding of LDL to plasma membrane [4] in 
cultured mammalian cells. 
The question then arises as to whether it is an ox- 
ysterol, rather than cholesterol itself, that 
modulates these mechanisms of cholesterol supply 
[5]. 26-Hydroxycholesterol (cholest-5-ene-3fl,26- 
diol) is present in human meconium [6] and serum 
[7], and occurs in healthy and diseased human 
aorta [8,9]. Since this oxysterol is reported to 
inhibit HMG-CoA reductase activity in a mam- 
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malian cell system [10], the possibility that it could 
also interfere with receptor-mediated LDL meta- 
bolism was explored. Cultured human fibroblasts 
were used as a cellular system. 
2. EXPERIMENTAL 
26(S)-Hydroxycholesterol and its 26(R) epimer 
were obtained from Research Plus (Bayonne, N J). 
Its purity was assessed by chromatographic tech- 
niques [9]. Commercial heparin (Na salt) was a gift 
of Crinos SpA (Como, Italy). Na125I (carrier-free; 
spec. act. 16.7 mCi//zg) in 0.1 M NaOH was pur- 
chased from Amersham (Amersham, England). 
Culture media, buffers, fetal calf serum and 
disposable material were obtained as previously 
reported [11]. 
2.1. Cells 
Human skin fibroblasts were grown from ex- 
plants of skin biopsies obtained from nor- 
molipidemic clinically healthy individuals. Cells 
were grown in monolayer as in [11] and used be- 
tween the fifth and fifteenth passage. 
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Table 1 
Degradation of 125I-LDL in human fibroblasts: effect of 
cholesterol and 26(S)-hydroxycholesterol 
Sterol 125I-LDL degradation 
(ng LDL protein/mg cell 
protein) 
None 159.0 (452) 
Cholesterol 
0.1 ~M 175.2 (464) 
2.0~M 162.4 (470) 
6.0~M 120.5 (461) 
25(S)-Hydroxycholesterol 
0.1/zM 172.8 (445) 
2.0/zM 60.0 (460) 
6.0/zM 7.0 (440) 
In parentheses is given the mean content of total cellular 
protein (ug/dish) 
2.2. Lipoproteins 
LDL (d 1.019-1.063 g/ml) were isolated from 
plasma of clinically healthy normolipidemic 
volunteers by sequential preparative ultracen- 
trifugation [12]. LDL were iodinated with 125I by 
the monochloride procedure of McFarlane [13] as 
modified for lipoproteins [14], and sterilized by 
filtration (spec. act. 110-234 cpm/ng LDL pro- 
tein). Lipoprotein-deprived serum (LPDS) was 
prepared by ultracentrifugation [11]. 
2.3. Binding, uptake and degradation of ~25I-LDL 
All experiments were performed in a similar for- 
mat. Confluent monolayers of cells were prein- 
cubated for 24h  at 37°C in F- l l  medium 
containing 5070 LPDS to induce LDL receptors [ 1], 
in the presence of 26-hydroxycholesterol at the 
concentrations indicated. Control dishes contained 
the same volume of ethanol (1°70 final concentra- 
tion). After this time a fixed concentration 
(10/~g/ml of LDL protein: experiments reported in 
fig.1 and table 1) or increasing concentrations of
125I-LDL (experiment reported in fig.2) were add- 
ed to medium and the incubation was continued 
for a further 4 h. 
Cell surface specific binding, uptake (binding + 
internalization) and degradation of 125I-LDL were 
evaluated as reported [11]. Each experimenai point 
represents the average value of duplicate or 
triplicate incubations. 
Cell viability was routinely assessed by trypan 
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Fig. l. Uptake and degradation of '25I-LDL by human fibroblasts: effect of 26(R)- and 26(S)-hydroxycholesterol. 
78 
Volume 218, number 1 FEBS LETTERS June 1987 
blue exclusion and found to be greater than 90°7o 
under all experimental conditions. The protein 
content of cell monolayers, determined according 
to Lowry et al. [15], was not affected by incuba- 
tion with 26-hydroxycholesteroh an example is 
reported in table 1. 
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3. RESULTS 
26(S)-Hydroxycholesterol and its 26(R) epimer, 
tested at concentrations ranging between 0.01 and 
10/zM, decreased cellular uptake (panel A) and 
degradation (panel B) of 125I-LDL (fig. 1); the in- 
hibition was dose-dependent with no apparent dif- 
ference between the two isomers. 
Freshly crystallized cholesterol was less efficient 
in reducing cellular degradation of ~25I-LDL (table 
1). In the experiment depicted in fig.2, the effect of 
a fixed concentration of 26(S)-hydroxycholesterol 
(10/zM) on specific cell surface binding of 1251- 
LDL was evaluated at 37°C as a function of 
lipoprotein concentrations. To distinguish the 
amount of 125I-LDL bound to the receptor from 
that which has been internalized, heparin (which 
selectively releases the 125I-LDL bound to the cell 
surface receptor) was used, according to Goldstein 
et al. [16]. In the presence of the sterol, 125I-LDL 
binding reached a plateau at lower values (upper 
panel). Scatchard analysis indicated that the ox- 
ysterol decreased the maximum amount of LDL 
bound at receptor saturation (317 vs 72 ng 1251- 
LDL protein/mg cell protein), without affecting 
the binding affinity of the ligand (39 nM). 
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Fig.2. Cell surface binding of IzSI-LDL by human 
fibroblasts: effect of 26(S)-hydroxycholesterol; the
lower panel represents the Scatchard analysis of the 
data. (o------o) r = 0.97, p < 0.01; (o-----~) r = 0.90, p < 
0.05. 
4. DISCUSSION 
In recent years attention has been focussed on 
the biological properties of oxysterols. These com- 
pounds, in addition to other effects, suppress 
sterol biosynthesis n vivo as well as in cell cultures 
[5,16] by depressing the activity of HMG-CoA 
reductase [4,5,10]. The possibility that feed-back 
regulation of sterol biosynthesis could be brought 
about by an oxygenated sterol rather than by 
cholesterol itself has been considered [5]. 
25-Hydroxy- and 26-hydroxycholesterols are 
among the most potent inhibitors of cholesterol 
biosynthesis, and the former was reported by 
Brown and Goldstein [4] to decrease receptor- 
mediated LDL uptake in human fibroblasts: the 
results of our experiments indicate that such an ac- 
tion is shared by 26-hydroxycholesterol. 
25-Hydroxycholesterol is considered an auto- 
oxidation product of cholesterol [8,17], and its oc- 
currence in vivo as part of a metabolic pathway is 
disputed [I0,18]. In contrast, 26-hydroxycholester- 
ol is the result of mitochondrial C27-steroid 
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26-hydroxylase [19,20], is an intermediate in the 
synthesis of bile acids [21], and is present in the 
serum of normal adults [7]. 
Esterman et al. [10] propose that 26-hydroxy- 
cholesterol has a selective biological role in the 
regulation of cholesterol biosynthesis. Our results 
show that this oxygenated sterol inhibits LDL 
pathway in human fibroblasts, thus also inter- 
fering with the extracellular source of cholesterol 
in mammalian cells in culture [1]. This effect in- 
volves a reduction of LDL-binding sites with no 
change in their affinity for the ligand, and occurs 
at concentrations of 26-hydroxycholesterol 
(ECso-  1/zM) not greatly different from those 
observed in human serum (0.23-0.64/zM) [7]. 
These results, in the light of the presence of 
26-hydroxycholesterol in human LDL [7], support 
a possible regulatory role of this physiological ox- 
ysterol in cellular cholesterol homeostasis. 
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